Kristin Yarema, Ph.D.
President, Cell Therapy
Dr. Yarema joined Poseida as our President, Cell Therapy in April 2023, bringing extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy. Prior to Poseida she served as Chief Commercial Officer at Atara Biotherapeutics, where she led the commercialization of EBVALLO™️, which became the world’s first marketed allogeneic T cell therapy after receiving regulatory approval in Europe for the treatment of a rare lymphoma. Previously Dr. Yarema held a series of U.S. and global commercial leadership roles at Amgen, including most recently Vice President & Therapeutic Area Head for Global Product Strategy & Commercial Innovation in Hematology-Oncology. Earlier in her career, Dr. Yarema worked at Novartis and McKinsey & Company. Dr. Yarema holds a Ph.D. in Biochemical Engineering from University of California, Berkeley and is a graduate of Stanford University, where she earned dual bachelor’s degrees in Chemical Engineering and English. She serves on the boards of directors of the Celiac Disease Foundation and the Alliance for Regenerative Medicine.